

## Improving Outcomes Using Novel Drug Delivery in Alzheimer's Disease

Interviews are based on data presented at the 10th International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy, February 28 – March 1, 2008, Hong Kong, China\*

\*PeerView Press is an independent publisher of conference news and medical education programmes.

Participate in the CME-certified multimedia activity featured in this podcast.  
Go online now at:

[www.peerviewpress.com/pc1/s475](http://www.peerviewpress.com/pc1/s475)

Cette présentation contient des sous-titres en français.

### Programme Faculty

#### Interviewees

**Howard Dombrower, MD**

Division of Geriatric Medicine  
Faculty of Medicine  
The University of Toronto  
Toronto, Ontario

**Alain Robillard, MD, FRCPC**

Associate Clinical Professor of Neurology  
Maisonneuve-Rosemont Hospital  
Montréal, Québec

#### Course Director and CME Reviewer

**Kathryn Bell, MD, FRCPC**

Clinical Instructor, Geriatric Medicine  
University of British Columbia  
Geriatrician, Vancouver Coastal Health  
Vancouver, British Columbia



This CME activity is jointly sponsored by the University of British Columbia Division of Continuing Professional Development and Knowledge Translation and PeerView Press.

PeerView Press, 1801, avenue McGill College, Suite 500, Montréal, Québec, H3A 2N4

© 2000-2008, PeerView Press

To complete the post-test and evaluation for CME credit, please click here:  
[www.peerviewpress.com/pc1/s475](http://www.peerviewpress.com/pc1/s475)

This activity is supported by an educational grant from Novartis Pharmaceuticals Canada Inc.

## Improving Outcomes Using Novel Drug Delivery in Alzheimer's Disease

Participate in the CME-certified multimedia activity featured in this podcast.  
Go online now at:

[www.peerviewpress.com/pc1/s475](http://www.peerviewpress.com/pc1/s475)

### General Information

As an organisation accredited to sponsor continuing medical education for physicians by the Committee on Accreditation of Canadian Medical Schools (CACMS), the UBC Division of Continuing Professional Development and Knowledge Translation designates this educational programme as meeting the accreditation criteria of the College of Family Physicians of Canada for up to 0.5 Mainpro-M1 credits. This programme is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification programme of the Royal College of Physicians and Surgeons of Canada. This programme has been reviewed and approved by UBC Division of Continuing Professional Development and Knowledge Translation. Each physician should claim only those credits he/she actually spent in the activity.

Media:	Internet
Release Date:	June 13, 2008
Expiration Date:	June 12, 2009
Estimated time to complete activity:	30 minutes
Sponsorship:	This CME activity is jointly sponsored by the University of British Columbia Division of Continuing Professional Development and Knowledge Translation and PeerView Press.
Support:	This activity is supported by an educational grant from Novartis Pharmaceuticals Canada Inc.

### Faculty Disclosures/Conflict of Interest Policy

The University of British Columbia Division of Continuing Professional Development and Knowledge Translation has a conflict of interest policy that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.

**Howard Dombrower, MD**, has a financial interest/relationship or affiliation in the form of: Honorarium from Janssen-Ortho Inc.; Novartis Pharmaceuticals Canada Inc.; and Pfizer Canada Inc.  
Other Financial or Material Support from Novartis Pharmaceuticals Canada Inc.

**Alain Robillard, MD, FRCPC**, has a financial interest/relationship or affiliation in the form of: Advisory Board for AstraZeneca Pharmaceuticals LP; GlaxoSmithKline Inc.; Janssen-Ortho Inc.; Lundbeck A/S; Novartis Pharmaceuticals Canada Inc.; Ono Pharmaceutical Co., Ltd.; Pfizer Canada Inc.; sanofi-aventis; and Voyager Pharmaceutical Corp.  
Grant/Research Support from AstraZeneca Pharmaceuticals LP; GlaxoSmithKline Inc.; Janssen-Ortho Inc.; Lundbeck A/S; Novartis Pharmaceuticals Canada Inc.; Ono Pharmaceutical Co., Ltd.; Pfizer Canada Inc.; sanofi-aventis; and Voyager Pharmaceutical Corp.  
Honoraria from AstraZeneca Pharmaceuticals LP; GlaxoSmithKline Inc.; Janssen-Ortho Inc.; Lundbeck A/S; Novartis Pharmaceuticals Canada Inc.; Ono Pharmaceutical Co., Ltd.; Pfizer Canada Inc.; sanofi-aventis; and Voyager Pharmaceutical Corp.  
Speakers Bureau participant with AstraZeneca Pharmaceuticals LP; GlaxoSmithKline Inc.; Janssen-Ortho Inc.; Lundbeck A/S; Novartis Pharmaceuticals Canada Inc.; Ono Pharmaceutical Co., Ltd.; Pfizer Canada Inc.; sanofi-aventis; and Voyager Pharmaceutical Corp.

To complete the post-test and evaluation for CME credit, please click here:  
[www.peerviewpress.com/pc1/s475](http://www.peerviewpress.com/pc1/s475)

## Improving Outcomes Using Novel Drug Delivery in Alzheimer's Disease

Participate in the CME-certified multimedia activity featured in this podcast.  
Go online now at:

[www.peerviewpress.com/pc1/s475](http://www.peerviewpress.com/pc1/s475)

**Course Director and CME Reviewer: Kathryn Bell, MD**, has a financial interest/relationship or affiliation in the form of:

*Honoraria* from Novartis Pharmaceuticals Canada Inc. and Pfizer Canada Inc.

### Disclosure of Unlabelled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labelled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabelled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

### Target Audience

This activity has been designed to meet the educational needs of Canadian general practitioners and specialists.

### Programme Description

A review of recent data on cholinesterase inhibitors and ways to improve compliance, reduce tolerability issues and ameliorate efficacy. Drs. Dombrower and Robillard discuss data presented at the 10th International Hong Kong/Springfield Symposium on Alzheimer Therapy as well as recently published data.

### Educational Objectives

Upon completion of this activity, participants should be better able to:

- Understand the use of cholinesterase inhibitors (ChEIs) as treatment for dementia of the Alzheimer type
- Discuss the main goals of ChEI use in Alzheimer's disease (AD) and the importance of patient compliance in achieving these goals
- Understand the different delivery systems currently available for ChEIs in the treatment of AD, and how some will improve compliance, tolerability and possibly efficacy of treatment

### Hardware/Software Requirements

PeerView Press requires version 6.x browsers or higher from Microsoft or Netscape. Certain activities may require additional software to view. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Reader®, and Adobe® Flash Player.

### Privacy Policy

PeerView Press shares your concerns about maintaining the privacy of personal information collected on the Internet. PeerView Press ensures that confidentiality of data relating to individual visitors to a medical/health web site, including their identity, is respected by this web site. The web site owners undertake to honour or exceed the legal requirements of medical/health information privacy that apply in the country and state where the web site and mirror sites are located.

To complete the post-test and evaluation for CME credit, please click here:  
[www.peerviewpress.com/pc1/s475](http://www.peerviewpress.com/pc1/s475)

## Improving Outcomes Using Novel Drug Delivery in Alzheimer's Disease

Participate in the CME-certified multimedia activity featured in this podcast.

Go online now at:

[www.peerviewpress.com/pc1/s475](http://www.peerviewpress.com/pc1/s475)

### Privacy Policy Changes:

Minor changes to our privacy policy may occur. If privacy policies change in a way that significantly affects the way we handle personal information, we will not use the information we have previously collected without obtaining consent. We will post all privacy policy changes on our web site in a timely manner.

### Collection of Personal Information from Site Users:

Visitors to PeerView Press can access and browse the site, without disclosing any personally identifiable information. PeerView Press does track some information provided by your browser, such as the time and date of access, the web site you came from, the type of browser used, and other information that does not personally identify you. Visitors registering for services such as email updates, or completing programme evaluation forms are requested to provide personal information, such as name, contact information, and medical specialty. We clearly label which information is required for registration, and which information is optional, on our registration forms. PeerView Press will not collect personally identifiable information without consent and will not share this data with any external partners.

[Click here to see the full PeerView Press Privacy Policy](#)

### Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

To complete the post-test and evaluation for CME credit, please click here:  
[www.peerviewpress.com/pc1/s475](http://www.peerviewpress.com/pc1/s475)